Racura Oncology Limited
Racura Oncology Receives First Site Approval for Seamless Phase 2b/3 EMILI Trial of RC220 in Relapsed or Refractory Acute Myeloid Leukemia
Single-cycle bridge-to-transplant trial builds on two prior AML studies of bisantrene at Sheba; Phase 2b dose-optimization stage (up to 68 patients)…
